nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—liver cancer	0.237	0.395	CbGaD
Thalidomide—CYP2E1—liver cancer	0.183	0.304	CbGaD
Thalidomide—CYP1A1—liver cancer	0.18	0.3	CbGaD
Thalidomide—CYP3A5—Sorafenib—liver cancer	0.0187	0.31	CbGbCtD
Thalidomide—CYP2C19—Sorafenib—liver cancer	0.0151	0.25	CbGbCtD
Thalidomide—CYP1A2—Sorafenib—liver cancer	0.0139	0.231	CbGbCtD
Thalidomide—CYP2C9—Sorafenib—liver cancer	0.0125	0.208	CbGbCtD
Thalidomide—Pomalidomide—TNF—liver cancer	0.00151	0.313	CrCbGaD
Thalidomide—Menadione—F2—liver cancer	0.00137	0.284	CrCbGaD
Thalidomide—Menadione—MTHFR—liver cancer	0.000881	0.182	CrCbGaD
Thalidomide—Menadione—CYP2E1—liver cancer	0.000536	0.111	CrCbGaD
Thalidomide—Menadione—CYP1A1—liver cancer	0.000528	0.109	CrCbGaD
Thalidomide—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000145	0.000848	CcSEcCtD
Thalidomide—Face oedema—Doxorubicin—liver cancer	0.000144	0.000841	CcSEcCtD
Thalidomide—Muscular weakness—Epirubicin—liver cancer	0.000142	0.00083	CcSEcCtD
Thalidomide—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000142	0.00083	CcSEcCtD
Thalidomide—Cardiac arrest—Doxorubicin—liver cancer	0.000141	0.000828	CcSEcCtD
Thalidomide—Dizziness—Sorafenib—liver cancer	0.000141	0.000828	CcSEcCtD
Thalidomide—Mood swings—Doxorubicin—liver cancer	0.000141	0.000825	CcSEcCtD
Thalidomide—Abdominal distension—Epirubicin—liver cancer	0.00014	0.000819	CcSEcCtD
Thalidomide—Ataxia—Doxorubicin—liver cancer	0.00014	0.000819	CcSEcCtD
Thalidomide—Blood creatinine increased—Doxorubicin—liver cancer	0.000139	0.000816	CcSEcCtD
Thalidomide—Influenza—Epirubicin—liver cancer	0.000139	0.000814	CcSEcCtD
Thalidomide—Dysphagia—Epirubicin—liver cancer	0.000139	0.000814	CcSEcCtD
Thalidomide—Dehydration—Doxorubicin—liver cancer	0.000138	0.00081	CcSEcCtD
Thalidomide—Eosinophilia—Epirubicin—liver cancer	0.000138	0.000806	CcSEcCtD
Thalidomide—Liver function test abnormal—Doxorubicin—liver cancer	0.000137	0.000804	CcSEcCtD
Thalidomide—Dry skin—Doxorubicin—liver cancer	0.000136	0.000798	CcSEcCtD
Thalidomide—Pancreatitis—Epirubicin—liver cancer	0.000136	0.000798	CcSEcCtD
Thalidomide—Vomiting—Sorafenib—liver cancer	0.000136	0.000796	CcSEcCtD
Thalidomide—Orthostatic hypotension—Doxorubicin—liver cancer	0.000136	0.000795	CcSEcCtD
Thalidomide—Hypokalaemia—Doxorubicin—liver cancer	0.000135	0.000793	CcSEcCtD
Thalidomide—Angina pectoris—Epirubicin—liver cancer	0.000135	0.000792	CcSEcCtD
Thalidomide—Rash—Sorafenib—liver cancer	0.000135	0.000789	CcSEcCtD
Thalidomide—Dermatitis—Sorafenib—liver cancer	0.000135	0.000789	CcSEcCtD
Thalidomide—Breast disorder—Doxorubicin—liver cancer	0.000134	0.000787	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000134	0.000784	CcSEcCtD
Thalidomide—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000134	0.000784	CcSEcCtD
Thalidomide—Headache—Sorafenib—liver cancer	0.000134	0.000784	CcSEcCtD
Thalidomide—Bronchitis—Epirubicin—liver cancer	0.000134	0.000782	CcSEcCtD
Thalidomide—Pancytopenia—Epirubicin—liver cancer	0.000132	0.000773	CcSEcCtD
Thalidomide—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000131	0.000768	CcSEcCtD
Thalidomide—Muscular weakness—Doxorubicin—liver cancer	0.000131	0.000768	CcSEcCtD
Thalidomide—Neutropenia—Epirubicin—liver cancer	0.00013	0.000761	CcSEcCtD
Thalidomide—Abdominal distension—Doxorubicin—liver cancer	0.000129	0.000758	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Epirubicin—liver cancer	0.000129	0.000756	CcSEcCtD
Thalidomide—Dysphagia—Doxorubicin—liver cancer	0.000129	0.000753	CcSEcCtD
Thalidomide—Influenza—Doxorubicin—liver cancer	0.000129	0.000753	CcSEcCtD
Thalidomide—Pollakiuria—Epirubicin—liver cancer	0.000128	0.000752	CcSEcCtD
Thalidomide—Eosinophilia—Doxorubicin—liver cancer	0.000127	0.000745	CcSEcCtD
Thalidomide—Nausea—Sorafenib—liver cancer	0.000127	0.000744	CcSEcCtD
Thalidomide—Photosensitivity reaction—Epirubicin—liver cancer	0.000127	0.000743	CcSEcCtD
Thalidomide—Weight increased—Epirubicin—liver cancer	0.000127	0.00074	CcSEcCtD
Thalidomide—Pancreatitis—Doxorubicin—liver cancer	0.000126	0.000738	CcSEcCtD
Thalidomide—Weight decreased—Epirubicin—liver cancer	0.000126	0.000736	CcSEcCtD
Thalidomide—Hyperglycaemia—Epirubicin—liver cancer	0.000125	0.000734	CcSEcCtD
Thalidomide—Angina pectoris—Doxorubicin—liver cancer	0.000125	0.000733	CcSEcCtD
Thalidomide—Pneumonia—Epirubicin—liver cancer	0.000125	0.00073	CcSEcCtD
Thalidomide—Infestation NOS—Epirubicin—liver cancer	0.000124	0.000725	CcSEcCtD
Thalidomide—Drowsiness—Epirubicin—liver cancer	0.000124	0.000725	CcSEcCtD
Thalidomide—Infestation—Epirubicin—liver cancer	0.000124	0.000725	CcSEcCtD
Thalidomide—Bronchitis—Doxorubicin—liver cancer	0.000124	0.000724	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000123	0.000719	CcSEcCtD
Thalidomide—Pancytopenia—Doxorubicin—liver cancer	0.000122	0.000715	CcSEcCtD
Thalidomide—Renal failure—Epirubicin—liver cancer	0.000122	0.000713	CcSEcCtD
Thalidomide—Neuropathy peripheral—Epirubicin—liver cancer	0.000121	0.000711	CcSEcCtD
Thalidomide—Stomatitis—Epirubicin—liver cancer	0.000121	0.000707	CcSEcCtD
Thalidomide—Conjunctivitis—Epirubicin—liver cancer	0.00012	0.000705	CcSEcCtD
Thalidomide—Neutropenia—Doxorubicin—liver cancer	0.00012	0.000704	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00012	0.0007	CcSEcCtD
Thalidomide—Sweating—Epirubicin—liver cancer	0.000119	0.000695	CcSEcCtD
Thalidomide—Pollakiuria—Doxorubicin—liver cancer	0.000119	0.000695	CcSEcCtD
Thalidomide—Haematuria—Epirubicin—liver cancer	0.000118	0.000692	CcSEcCtD
Thalidomide—Photosensitivity reaction—Doxorubicin—liver cancer	0.000117	0.000687	CcSEcCtD
Thalidomide—Weight increased—Doxorubicin—liver cancer	0.000117	0.000685	CcSEcCtD
Thalidomide—Epistaxis—Epirubicin—liver cancer	0.000117	0.000684	CcSEcCtD
Thalidomide—Weight decreased—Doxorubicin—liver cancer	0.000116	0.000681	CcSEcCtD
Thalidomide—Sinusitis—Epirubicin—liver cancer	0.000116	0.000681	CcSEcCtD
Thalidomide—Hyperglycaemia—Doxorubicin—liver cancer	0.000116	0.000679	CcSEcCtD
Thalidomide—Agranulocytosis—Epirubicin—liver cancer	0.000116	0.000677	CcSEcCtD
Thalidomide—Pneumonia—Doxorubicin—liver cancer	0.000115	0.000675	CcSEcCtD
Thalidomide—Infestation—Doxorubicin—liver cancer	0.000115	0.000671	CcSEcCtD
Thalidomide—Infestation NOS—Doxorubicin—liver cancer	0.000115	0.000671	CcSEcCtD
Thalidomide—Drowsiness—Doxorubicin—liver cancer	0.000115	0.000671	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000114	0.000665	CcSEcCtD
Thalidomide—Bradycardia—Epirubicin—liver cancer	0.000113	0.000663	CcSEcCtD
Thalidomide—Renal failure—Doxorubicin—liver cancer	0.000113	0.00066	CcSEcCtD
Thalidomide—Neuropathy peripheral—Doxorubicin—liver cancer	0.000112	0.000658	CcSEcCtD
Thalidomide—Stomatitis—Doxorubicin—liver cancer	0.000112	0.000654	CcSEcCtD
Thalidomide—Rhinitis—Epirubicin—liver cancer	0.000112	0.000653	CcSEcCtD
Thalidomide—Conjunctivitis—Doxorubicin—liver cancer	0.000111	0.000652	CcSEcCtD
Thalidomide—Hepatitis—Epirubicin—liver cancer	0.000111	0.000651	CcSEcCtD
Thalidomide—Hypoaesthesia—Epirubicin—liver cancer	0.000111	0.000648	CcSEcCtD
Thalidomide—Pharyngitis—Epirubicin—liver cancer	0.00011	0.000646	CcSEcCtD
Thalidomide—Sweating—Doxorubicin—liver cancer	0.00011	0.000643	CcSEcCtD
Thalidomide—Urinary tract disorder—Epirubicin—liver cancer	0.00011	0.000643	CcSEcCtD
Thalidomide—Oedema peripheral—Epirubicin—liver cancer	0.00011	0.000641	CcSEcCtD
Thalidomide—Haematuria—Doxorubicin—liver cancer	0.000109	0.00064	CcSEcCtD
Thalidomide—Urethral disorder—Epirubicin—liver cancer	0.000109	0.000638	CcSEcCtD
Thalidomide—Epistaxis—Doxorubicin—liver cancer	0.000108	0.000633	CcSEcCtD
Thalidomide—Sinusitis—Doxorubicin—liver cancer	0.000108	0.00063	CcSEcCtD
Thalidomide—Visual impairment—Epirubicin—liver cancer	0.000107	0.000628	CcSEcCtD
Thalidomide—Agranulocytosis—Doxorubicin—liver cancer	0.000107	0.000626	CcSEcCtD
Thalidomide—Erythema multiforme—Epirubicin—liver cancer	0.000105	0.000616	CcSEcCtD
Thalidomide—Bradycardia—Doxorubicin—liver cancer	0.000105	0.000613	CcSEcCtD
Thalidomide—Eye disorder—Epirubicin—liver cancer	0.000104	0.000609	CcSEcCtD
Thalidomide—Tinnitus—Epirubicin—liver cancer	0.000104	0.000607	CcSEcCtD
Thalidomide—Cardiac disorder—Epirubicin—liver cancer	0.000103	0.000604	CcSEcCtD
Thalidomide—Rhinitis—Doxorubicin—liver cancer	0.000103	0.000604	CcSEcCtD
Thalidomide—Hepatitis—Doxorubicin—liver cancer	0.000103	0.000603	CcSEcCtD
Thalidomide—Hypoaesthesia—Doxorubicin—liver cancer	0.000102	0.0006	CcSEcCtD
Thalidomide—Pharyngitis—Doxorubicin—liver cancer	0.000102	0.000598	CcSEcCtD
Thalidomide—Urinary tract disorder—Doxorubicin—liver cancer	0.000102	0.000595	CcSEcCtD
Thalidomide—Oedema peripheral—Doxorubicin—liver cancer	0.000101	0.000594	CcSEcCtD
Thalidomide—Angiopathy—Epirubicin—liver cancer	0.000101	0.000591	CcSEcCtD
Thalidomide—Urethral disorder—Doxorubicin—liver cancer	0.000101	0.000591	CcSEcCtD
Thalidomide—Immune system disorder—Epirubicin—liver cancer	0.0001	0.000588	CcSEcCtD
Thalidomide—Mediastinal disorder—Epirubicin—liver cancer	0.0001	0.000587	CcSEcCtD
Thalidomide—Chills—Epirubicin—liver cancer	9.98e-05	0.000584	CcSEcCtD
Thalidomide—Arrhythmia—Epirubicin—liver cancer	9.94e-05	0.000582	CcSEcCtD
Thalidomide—Visual impairment—Doxorubicin—liver cancer	9.92e-05	0.000581	CcSEcCtD
Thalidomide—Alopecia—Epirubicin—liver cancer	9.83e-05	0.000575	CcSEcCtD
Thalidomide—Mental disorder—Epirubicin—liver cancer	9.75e-05	0.00057	CcSEcCtD
Thalidomide—Erythema multiforme—Doxorubicin—liver cancer	9.73e-05	0.00057	CcSEcCtD
Thalidomide—Malnutrition—Epirubicin—liver cancer	9.69e-05	0.000567	CcSEcCtD
Thalidomide—Eye disorder—Doxorubicin—liver cancer	9.62e-05	0.000563	CcSEcCtD
Thalidomide—Tinnitus—Doxorubicin—liver cancer	9.6e-05	0.000562	CcSEcCtD
Thalidomide—Cardiac disorder—Doxorubicin—liver cancer	9.55e-05	0.000559	CcSEcCtD
Thalidomide—Flatulence—Epirubicin—liver cancer	9.54e-05	0.000559	CcSEcCtD
Thalidomide—Tension—Epirubicin—liver cancer	9.5e-05	0.000556	CcSEcCtD
Thalidomide—Dysgeusia—Epirubicin—liver cancer	9.48e-05	0.000555	CcSEcCtD
Thalidomide—Nervousness—Epirubicin—liver cancer	9.41e-05	0.000551	CcSEcCtD
Thalidomide—Back pain—Epirubicin—liver cancer	9.37e-05	0.000548	CcSEcCtD
Thalidomide—Angiopathy—Doxorubicin—liver cancer	9.34e-05	0.000547	CcSEcCtD
Thalidomide—Muscle spasms—Epirubicin—liver cancer	9.31e-05	0.000545	CcSEcCtD
Thalidomide—Immune system disorder—Doxorubicin—liver cancer	9.3e-05	0.000544	CcSEcCtD
Thalidomide—Mediastinal disorder—Doxorubicin—liver cancer	9.28e-05	0.000543	CcSEcCtD
Thalidomide—Chills—Doxorubicin—liver cancer	9.24e-05	0.000541	CcSEcCtD
Thalidomide—Arrhythmia—Doxorubicin—liver cancer	9.2e-05	0.000538	CcSEcCtD
Thalidomide—Vision blurred—Epirubicin—liver cancer	9.13e-05	0.000534	CcSEcCtD
Thalidomide—Alopecia—Doxorubicin—liver cancer	9.1e-05	0.000532	CcSEcCtD
Thalidomide—Mental disorder—Doxorubicin—liver cancer	9.02e-05	0.000528	CcSEcCtD
Thalidomide—Ill-defined disorder—Epirubicin—liver cancer	8.99e-05	0.000526	CcSEcCtD
Thalidomide—Malnutrition—Doxorubicin—liver cancer	8.96e-05	0.000525	CcSEcCtD
Thalidomide—Anaemia—Epirubicin—liver cancer	8.95e-05	0.000524	CcSEcCtD
Thalidomide—Agitation—Epirubicin—liver cancer	8.9e-05	0.000521	CcSEcCtD
Thalidomide—Flatulence—Doxorubicin—liver cancer	8.83e-05	0.000517	CcSEcCtD
Thalidomide—Tension—Doxorubicin—liver cancer	8.79e-05	0.000515	CcSEcCtD
Thalidomide—Dysgeusia—Doxorubicin—liver cancer	8.78e-05	0.000514	CcSEcCtD
Thalidomide—Malaise—Epirubicin—liver cancer	8.73e-05	0.000511	CcSEcCtD
Thalidomide—Nervousness—Doxorubicin—liver cancer	8.7e-05	0.000509	CcSEcCtD
Thalidomide—Vertigo—Epirubicin—liver cancer	8.7e-05	0.000509	CcSEcCtD
Thalidomide—Syncope—Epirubicin—liver cancer	8.69e-05	0.000508	CcSEcCtD
Thalidomide—Leukopenia—Epirubicin—liver cancer	8.67e-05	0.000507	CcSEcCtD
Thalidomide—Back pain—Doxorubicin—liver cancer	8.67e-05	0.000507	CcSEcCtD
Thalidomide—Muscle spasms—Doxorubicin—liver cancer	8.62e-05	0.000504	CcSEcCtD
Thalidomide—Palpitations—Epirubicin—liver cancer	8.56e-05	0.000501	CcSEcCtD
Thalidomide—Loss of consciousness—Epirubicin—liver cancer	8.51e-05	0.000498	CcSEcCtD
Thalidomide—Cough—Epirubicin—liver cancer	8.45e-05	0.000495	CcSEcCtD
Thalidomide—Vision blurred—Doxorubicin—liver cancer	8.45e-05	0.000494	CcSEcCtD
Thalidomide—Convulsion—Epirubicin—liver cancer	8.39e-05	0.000491	CcSEcCtD
Thalidomide—Hypertension—Epirubicin—liver cancer	8.36e-05	0.000489	CcSEcCtD
Thalidomide—Ill-defined disorder—Doxorubicin—liver cancer	8.31e-05	0.000487	CcSEcCtD
Thalidomide—Anaemia—Doxorubicin—liver cancer	8.28e-05	0.000485	CcSEcCtD
Thalidomide—Myalgia—Epirubicin—liver cancer	8.25e-05	0.000483	CcSEcCtD
Thalidomide—Chest pain—Epirubicin—liver cancer	8.25e-05	0.000483	CcSEcCtD
Thalidomide—Arthralgia—Epirubicin—liver cancer	8.25e-05	0.000483	CcSEcCtD
Thalidomide—Agitation—Doxorubicin—liver cancer	8.24e-05	0.000482	CcSEcCtD
Thalidomide—Anxiety—Epirubicin—liver cancer	8.22e-05	0.000481	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	8.19e-05	0.000479	CcSEcCtD
Thalidomide—Discomfort—Epirubicin—liver cancer	8.15e-05	0.000477	CcSEcCtD
Thalidomide—Malaise—Doxorubicin—liver cancer	8.08e-05	0.000473	CcSEcCtD
Thalidomide—Dry mouth—Epirubicin—liver cancer	8.06e-05	0.000472	CcSEcCtD
Thalidomide—Vertigo—Doxorubicin—liver cancer	8.05e-05	0.000471	CcSEcCtD
Thalidomide—Syncope—Doxorubicin—liver cancer	8.04e-05	0.00047	CcSEcCtD
Thalidomide—Leukopenia—Doxorubicin—liver cancer	8.02e-05	0.000469	CcSEcCtD
Thalidomide—Confusional state—Epirubicin—liver cancer	7.97e-05	0.000466	CcSEcCtD
Thalidomide—Palpitations—Doxorubicin—liver cancer	7.92e-05	0.000464	CcSEcCtD
Thalidomide—Oedema—Epirubicin—liver cancer	7.9e-05	0.000463	CcSEcCtD
Thalidomide—Loss of consciousness—Doxorubicin—liver cancer	7.88e-05	0.000461	CcSEcCtD
Thalidomide—Infection—Epirubicin—liver cancer	7.85e-05	0.00046	CcSEcCtD
Thalidomide—Cough—Doxorubicin—liver cancer	7.82e-05	0.000458	CcSEcCtD
Thalidomide—Shock—Epirubicin—liver cancer	7.78e-05	0.000455	CcSEcCtD
Thalidomide—Convulsion—Doxorubicin—liver cancer	7.76e-05	0.000454	CcSEcCtD
Thalidomide—Nervous system disorder—Epirubicin—liver cancer	7.75e-05	0.000454	CcSEcCtD
Thalidomide—Thrombocytopenia—Epirubicin—liver cancer	7.74e-05	0.000453	CcSEcCtD
Thalidomide—Hypertension—Doxorubicin—liver cancer	7.74e-05	0.000453	CcSEcCtD
Thalidomide—Tachycardia—Epirubicin—liver cancer	7.71e-05	0.000452	CcSEcCtD
Thalidomide—Skin disorder—Epirubicin—liver cancer	7.68e-05	0.000449	CcSEcCtD
Thalidomide—Hyperhidrosis—Epirubicin—liver cancer	7.64e-05	0.000447	CcSEcCtD
Thalidomide—Arthralgia—Doxorubicin—liver cancer	7.63e-05	0.000447	CcSEcCtD
Thalidomide—Myalgia—Doxorubicin—liver cancer	7.63e-05	0.000447	CcSEcCtD
Thalidomide—Chest pain—Doxorubicin—liver cancer	7.63e-05	0.000447	CcSEcCtD
Thalidomide—Anxiety—Doxorubicin—liver cancer	7.6e-05	0.000445	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	7.58e-05	0.000443	CcSEcCtD
Thalidomide—Discomfort—Doxorubicin—liver cancer	7.54e-05	0.000441	CcSEcCtD
Thalidomide—Anorexia—Epirubicin—liver cancer	7.53e-05	0.000441	CcSEcCtD
Thalidomide—Dry mouth—Doxorubicin—liver cancer	7.46e-05	0.000437	CcSEcCtD
Thalidomide—Hypotension—Epirubicin—liver cancer	7.39e-05	0.000432	CcSEcCtD
Thalidomide—Confusional state—Doxorubicin—liver cancer	7.37e-05	0.000432	CcSEcCtD
Thalidomide—Oedema—Doxorubicin—liver cancer	7.31e-05	0.000428	CcSEcCtD
Thalidomide—Infection—Doxorubicin—liver cancer	7.27e-05	0.000425	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Epirubicin—liver cancer	7.2e-05	0.000421	CcSEcCtD
Thalidomide—Shock—Doxorubicin—liver cancer	7.2e-05	0.000421	CcSEcCtD
Thalidomide—Nervous system disorder—Doxorubicin—liver cancer	7.17e-05	0.00042	CcSEcCtD
Thalidomide—Thrombocytopenia—Doxorubicin—liver cancer	7.16e-05	0.000419	CcSEcCtD
Thalidomide—Insomnia—Epirubicin—liver cancer	7.15e-05	0.000418	CcSEcCtD
Thalidomide—Tachycardia—Doxorubicin—liver cancer	7.14e-05	0.000418	CcSEcCtD
Thalidomide—Skin disorder—Doxorubicin—liver cancer	7.1e-05	0.000416	CcSEcCtD
Thalidomide—Paraesthesia—Epirubicin—liver cancer	7.1e-05	0.000415	CcSEcCtD
Thalidomide—Hyperhidrosis—Doxorubicin—liver cancer	7.07e-05	0.000414	CcSEcCtD
Thalidomide—Dyspnoea—Epirubicin—liver cancer	7.05e-05	0.000412	CcSEcCtD
Thalidomide—Somnolence—Epirubicin—liver cancer	7.03e-05	0.000411	CcSEcCtD
Thalidomide—Anorexia—Doxorubicin—liver cancer	6.97e-05	0.000408	CcSEcCtD
Thalidomide—Dyspepsia—Epirubicin—liver cancer	6.96e-05	0.000407	CcSEcCtD
Thalidomide—Decreased appetite—Epirubicin—liver cancer	6.87e-05	0.000402	CcSEcCtD
Thalidomide—Hypotension—Doxorubicin—liver cancer	6.83e-05	0.0004	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Epirubicin—liver cancer	6.82e-05	0.000399	CcSEcCtD
Thalidomide—Fatigue—Epirubicin—liver cancer	6.81e-05	0.000399	CcSEcCtD
Thalidomide—Pain—Epirubicin—liver cancer	6.76e-05	0.000396	CcSEcCtD
Thalidomide—Constipation—Epirubicin—liver cancer	6.76e-05	0.000396	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Doxorubicin—liver cancer	6.66e-05	0.00039	CcSEcCtD
Thalidomide—Insomnia—Doxorubicin—liver cancer	6.62e-05	0.000387	CcSEcCtD
Thalidomide—Paraesthesia—Doxorubicin—liver cancer	6.57e-05	0.000384	CcSEcCtD
Thalidomide—Dyspnoea—Doxorubicin—liver cancer	6.52e-05	0.000382	CcSEcCtD
Thalidomide—Feeling abnormal—Epirubicin—liver cancer	6.51e-05	0.000381	CcSEcCtD
Thalidomide—Somnolence—Doxorubicin—liver cancer	6.5e-05	0.000381	CcSEcCtD
Thalidomide—Gastrointestinal pain—Epirubicin—liver cancer	6.46e-05	0.000378	CcSEcCtD
Thalidomide—Dyspepsia—Doxorubicin—liver cancer	6.44e-05	0.000377	CcSEcCtD
Thalidomide—Decreased appetite—Doxorubicin—liver cancer	6.36e-05	0.000372	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Doxorubicin—liver cancer	6.31e-05	0.00037	CcSEcCtD
Thalidomide—Fatigue—Doxorubicin—liver cancer	6.31e-05	0.000369	CcSEcCtD
Thalidomide—Urticaria—Epirubicin—liver cancer	6.28e-05	0.000368	CcSEcCtD
Thalidomide—Constipation—Doxorubicin—liver cancer	6.25e-05	0.000366	CcSEcCtD
Thalidomide—Pain—Doxorubicin—liver cancer	6.25e-05	0.000366	CcSEcCtD
Thalidomide—Abdominal pain—Epirubicin—liver cancer	6.25e-05	0.000366	CcSEcCtD
Thalidomide—Body temperature increased—Epirubicin—liver cancer	6.25e-05	0.000366	CcSEcCtD
Thalidomide—Feeling abnormal—Doxorubicin—liver cancer	6.03e-05	0.000353	CcSEcCtD
Thalidomide—Gastrointestinal pain—Doxorubicin—liver cancer	5.98e-05	0.00035	CcSEcCtD
Thalidomide—Hypersensitivity—Epirubicin—liver cancer	5.82e-05	0.000341	CcSEcCtD
Thalidomide—Urticaria—Doxorubicin—liver cancer	5.81e-05	0.00034	CcSEcCtD
Thalidomide—Abdominal pain—Doxorubicin—liver cancer	5.78e-05	0.000338	CcSEcCtD
Thalidomide—Body temperature increased—Doxorubicin—liver cancer	5.78e-05	0.000338	CcSEcCtD
Thalidomide—Asthenia—Epirubicin—liver cancer	5.67e-05	0.000332	CcSEcCtD
Thalidomide—Pruritus—Epirubicin—liver cancer	5.59e-05	0.000327	CcSEcCtD
Thalidomide—Diarrhoea—Epirubicin—liver cancer	5.41e-05	0.000317	CcSEcCtD
Thalidomide—Hypersensitivity—Doxorubicin—liver cancer	5.39e-05	0.000315	CcSEcCtD
Thalidomide—Asthenia—Doxorubicin—liver cancer	5.25e-05	0.000307	CcSEcCtD
Thalidomide—Dizziness—Epirubicin—liver cancer	5.23e-05	0.000306	CcSEcCtD
Thalidomide—Pruritus—Doxorubicin—liver cancer	5.17e-05	0.000303	CcSEcCtD
Thalidomide—Vomiting—Epirubicin—liver cancer	5.03e-05	0.000294	CcSEcCtD
Thalidomide—Diarrhoea—Doxorubicin—liver cancer	5e-05	0.000293	CcSEcCtD
Thalidomide—Rash—Epirubicin—liver cancer	4.98e-05	0.000292	CcSEcCtD
Thalidomide—Dermatitis—Epirubicin—liver cancer	4.98e-05	0.000291	CcSEcCtD
Thalidomide—Headache—Epirubicin—liver cancer	4.95e-05	0.00029	CcSEcCtD
Thalidomide—Dizziness—Doxorubicin—liver cancer	4.84e-05	0.000283	CcSEcCtD
Thalidomide—Nausea—Epirubicin—liver cancer	4.7e-05	0.000275	CcSEcCtD
Thalidomide—Vomiting—Doxorubicin—liver cancer	4.65e-05	0.000272	CcSEcCtD
Thalidomide—Rash—Doxorubicin—liver cancer	4.61e-05	0.00027	CcSEcCtD
Thalidomide—Dermatitis—Doxorubicin—liver cancer	4.61e-05	0.00027	CcSEcCtD
Thalidomide—Headache—Doxorubicin—liver cancer	4.58e-05	0.000268	CcSEcCtD
Thalidomide—Nausea—Doxorubicin—liver cancer	4.34e-05	0.000254	CcSEcCtD
Thalidomide—FGFR2—Disease—CDKN1A—liver cancer	6.71e-06	4.08e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HPGDS—liver cancer	6.65e-06	4.04e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—BRAF—liver cancer	6.65e-06	4.04e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP2E1—liver cancer	6.63e-06	4.03e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—liver cancer	6.62e-06	4.02e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—H2AFX—liver cancer	6.59e-06	4e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYCS—liver cancer	6.58e-06	4e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYCS—liver cancer	6.57e-06	3.99e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTA1—liver cancer	6.56e-06	3.99e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CD—liver cancer	6.56e-06	3.98e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—AKT1—liver cancer	6.52e-06	3.96e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NAT2—liver cancer	6.49e-06	3.94e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SERPINE1—liver cancer	6.49e-06	3.94e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—STAT3—liver cancer	6.48e-06	3.94e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GGT1—liver cancer	6.46e-06	3.92e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GOT1—liver cancer	6.46e-06	3.92e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GGT1—liver cancer	6.44e-06	3.91e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GOT1—liver cancer	6.44e-06	3.91e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	6.42e-06	3.9e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MTHFR—liver cancer	6.3e-06	3.83e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	6.25e-06	3.8e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	6.24e-06	3.79e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CD—liver cancer	6.22e-06	3.78e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALDOB—liver cancer	6.22e-06	3.78e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYCS—liver cancer	6.2e-06	3.77e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARA—liver cancer	6.18e-06	3.76e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTP1—liver cancer	6.16e-06	3.74e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SERPINE1—liver cancer	6.15e-06	3.74e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GOT1—liver cancer	6.09e-06	3.7e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GGT1—liver cancer	6.09e-06	3.7e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—HMOX1—liver cancer	6.08e-06	3.69e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HPGDS—liver cancer	6.07e-06	3.69e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	6.03e-06	3.67e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	6.03e-06	3.66e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—STAT3—liver cancer	5.98e-06	3.64e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTHFR—liver cancer	5.97e-06	3.63e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TERT—liver cancer	5.96e-06	3.62e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—liver cancer	5.95e-06	3.61e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CRABP1—liver cancer	5.93e-06	3.6e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PSMD10—liver cancer	5.93e-06	3.6e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PSMA4—liver cancer	5.93e-06	3.6e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KRAS—liver cancer	5.87e-06	3.56e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RAF1—liver cancer	5.85e-06	3.56e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTP1—liver cancer	5.8e-06	3.52e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTP1—liver cancer	5.79e-06	3.52e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GOT2—liver cancer	5.77e-06	3.51e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—HMOX1—liver cancer	5.72e-06	3.48e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MTOR—liver cancer	5.72e-06	3.47e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CB—liver cancer	5.72e-06	3.47e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—HMOX1—liver cancer	5.71e-06	3.47e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTM1—liver cancer	5.66e-06	3.44e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KRAS—liver cancer	5.57e-06	3.38e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MYC—liver cancer	5.56e-06	3.38e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RAF1—liver cancer	5.55e-06	3.38e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	5.55e-06	3.37e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—liver cancer	5.55e-06	3.37e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	5.49e-06	3.34e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTP1—liver cancer	5.47e-06	3.32e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP2E1—liver cancer	5.42e-06	3.3e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	5.42e-06	3.3e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MTOR—liver cancer	5.42e-06	3.3e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CB—liver cancer	5.42e-06	3.3e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PSMD10—liver cancer	5.41e-06	3.29e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PSMA4—liver cancer	5.41e-06	3.29e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—HMOX1—liver cancer	5.39e-06	3.28e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PIK3CA—liver cancer	5.39e-06	3.27e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP1A1—liver cancer	5.37e-06	3.26e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN1B—liver cancer	5.36e-06	3.26e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	5.34e-06	3.25e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTM1—liver cancer	5.33e-06	3.24e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTM1—liver cancer	5.32e-06	3.23e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CG—liver cancer	5.29e-06	3.22e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GOT2—liver cancer	5.26e-06	3.2e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CASP3—liver cancer	5.26e-06	3.19e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	5.25e-06	3.19e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2—liver cancer	5.25e-06	3.19e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HPGDS—liver cancer	5.19e-06	3.15e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	5.15e-06	3.13e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KRAS—liver cancer	5.14e-06	3.12e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCND1—liver cancer	5.12e-06	3.11e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PIK3CA—liver cancer	5.11e-06	3.11e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARG—liver cancer	5.11e-06	3.11e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—JUN—liver cancer	5.11e-06	3.1e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN1B—liver cancer	5.09e-06	3.09e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYCS—liver cancer	5.08e-06	3.08e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CTNNB1—liver cancer	5.07e-06	3.08e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP1A1—liver cancer	5.05e-06	3.07e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP1A1—liver cancer	5.04e-06	3.06e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTM1—liver cancer	5.02e-06	3.05e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APC—liver cancer	5.02e-06	3.05e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTHFR—liver cancer	5e-06	3.04e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CASP3—liver cancer	4.99e-06	3.03e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—liver cancer	4.99e-06	3.03e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GGT1—liver cancer	4.98e-06	3.03e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GOT1—liver cancer	4.98e-06	3.03e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2—liver cancer	4.98e-06	3.03e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MMP9—liver cancer	4.97e-06	3.02e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN1A—liver cancer	4.95e-06	3.01e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP2E1—liver cancer	4.95e-06	3.01e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARA—liver cancer	4.91e-06	2.98e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCND1—liver cancer	4.85e-06	2.95e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—JUN—liver cancer	4.84e-06	2.94e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK8—liver cancer	4.83e-06	2.94e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CTNNB1—liver cancer	4.81e-06	2.92e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.79e-06	2.91e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—liver cancer	4.77e-06	2.9e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—liver cancer	4.73e-06	2.87e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PIK3CA—liver cancer	4.72e-06	2.87e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—BRAF—liver cancer	4.72e-06	2.87e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MMP9—liver cancer	4.71e-06	2.86e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTHFR—liver cancer	4.71e-06	2.86e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTHFR—liver cancer	4.7e-06	2.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN1A—liver cancer	4.7e-06	2.85e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.7e-06	2.85e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CD—liver cancer	4.65e-06	2.83e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	4.64e-06	2.82e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYCS—liver cancer	4.63e-06	2.81e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PSMA4—liver cancer	4.62e-06	2.81e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PSMD10—liver cancer	4.62e-06	2.81e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARA—liver cancer	4.62e-06	2.81e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARA—liver cancer	4.61e-06	2.8e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—liver cancer	4.59e-06	2.79e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK8—liver cancer	4.58e-06	2.79e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GGT1—liver cancer	4.54e-06	2.76e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GOT1—liver cancer	4.54e-06	2.76e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—liver cancer	4.53e-06	2.75e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GOT2—liver cancer	4.5e-06	2.73e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTP1—liver cancer	4.47e-06	2.72e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—liver cancer	4.46e-06	2.71e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTHFR—liver cancer	4.44e-06	2.7e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—STAT3—liver cancer	4.42e-06	2.68e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CD—liver cancer	4.41e-06	2.68e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HMOX1—liver cancer	4.41e-06	2.68e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.41e-06	2.68e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—liver cancer	4.4e-06	2.68e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—liver cancer	4.37e-06	2.65e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SERPINE1—liver cancer	4.36e-06	2.65e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARA—liver cancer	4.36e-06	2.65e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—liver cancer	4.23e-06	2.57e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP2E1—liver cancer	4.23e-06	2.57e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CG—liver cancer	4.2e-06	2.55e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—STAT3—liver cancer	4.19e-06	2.55e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—liver cancer	4.18e-06	2.54e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—liver cancer	4.18e-06	2.54e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTM1—liver cancer	4.11e-06	2.5e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MYC—liver cancer	4.1e-06	2.49e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—liver cancer	4.09e-06	2.49e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.09e-06	2.49e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTP1—liver cancer	4.08e-06	2.48e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CB—liver cancer	4.06e-06	2.47e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARG—liver cancer	4.06e-06	2.47e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HMOX1—liver cancer	4.02e-06	2.44e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CG—liver cancer	3.96e-06	2.4e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYCS—liver cancer	3.95e-06	2.4e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CG—liver cancer	3.95e-06	2.4e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—RAF1—liver cancer	3.94e-06	2.39e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.91e-06	2.38e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP1A1—liver cancer	3.9e-06	2.37e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MYC—liver cancer	3.89e-06	2.37e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—liver cancer	3.88e-06	2.36e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GGT1—liver cancer	3.88e-06	2.36e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GOT1—liver cancer	3.88e-06	2.36e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—liver cancer	3.86e-06	2.34e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTOR—liver cancer	3.85e-06	2.34e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CB—liver cancer	3.85e-06	2.34e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARG—liver cancer	3.82e-06	2.32e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARG—liver cancer	3.81e-06	2.32e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KRAS—liver cancer	3.79e-06	2.3e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTM1—liver cancer	3.75e-06	2.28e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CG—liver cancer	3.73e-06	2.27e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CD—liver cancer	3.7e-06	2.25e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—liver cancer	3.65e-06	2.22e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTHFR—liver cancer	3.63e-06	2.21e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1B—liver cancer	3.61e-06	2.19e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARG—liver cancer	3.6e-06	2.19e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KRAS—liver cancer	3.6e-06	2.19e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARA—liver cancer	3.56e-06	2.17e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP1A1—liver cancer	3.55e-06	2.16e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTP1—liver cancer	3.49e-06	2.12e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CA—liver cancer	3.48e-06	2.12e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CD—liver cancer	3.48e-06	2.11e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CD—liver cancer	3.47e-06	2.11e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HMOX1—liver cancer	3.44e-06	2.09e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—liver cancer	3.43e-06	2.09e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—liver cancer	3.43e-06	2.08e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CTNNB1—liver cancer	3.41e-06	2.07e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—liver cancer	3.37e-06	2.05e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1A—liver cancer	3.33e-06	2.02e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTHFR—liver cancer	3.31e-06	2.01e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CA—liver cancer	3.31e-06	2.01e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CD—liver cancer	3.28e-06	1.99e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARA—liver cancer	3.25e-06	1.98e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—liver cancer	3.24e-06	1.97e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—liver cancer	3.22e-06	1.96e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CB—liver cancer	3.22e-06	1.96e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTM1—liver cancer	3.2e-06	1.95e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.2e-06	1.95e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—liver cancer	3.2e-06	1.94e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—liver cancer	3.09e-06	1.87e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—liver cancer	3.06e-06	1.86e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CG—liver cancer	3.05e-06	1.86e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP1A1—liver cancer	3.04e-06	1.85e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CB—liver cancer	3.03e-06	1.84e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CB—liver cancer	3.03e-06	1.84e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—STAT3—liver cancer	2.97e-06	1.81e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARG—liver cancer	2.95e-06	1.79e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—liver cancer	2.93e-06	1.78e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.92e-06	1.77e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CB—liver cancer	2.86e-06	1.74e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—liver cancer	2.85e-06	1.73e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTHFR—liver cancer	2.83e-06	1.72e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CG—liver cancer	2.78e-06	1.69e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARA—liver cancer	2.78e-06	1.69e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MYC—liver cancer	2.76e-06	1.68e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—liver cancer	2.75e-06	1.67e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—liver cancer	2.7e-06	1.64e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARG—liver cancer	2.69e-06	1.63e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CD—liver cancer	2.68e-06	1.63e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—liver cancer	2.65e-06	1.61e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KRAS—liver cancer	2.55e-06	1.55e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.49e-06	1.52e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CA—liver cancer	2.47e-06	1.5e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CD—liver cancer	2.45e-06	1.49e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—liver cancer	2.42e-06	1.47e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CG—liver cancer	2.38e-06	1.45e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CA—liver cancer	2.34e-06	1.42e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CB—liver cancer	2.34e-06	1.42e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARG—liver cancer	2.3e-06	1.4e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—liver cancer	2.17e-06	1.32e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CB—liver cancer	2.13e-06	1.3e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CD—liver cancer	2.09e-06	1.27e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—liver cancer	2.08e-06	1.26e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—liver cancer	2.06e-06	1.25e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—liver cancer	2.02e-06	1.23e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CA—liver cancer	1.96e-06	1.19e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—liver cancer	1.92e-06	1.16e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CA—liver cancer	1.85e-06	1.12e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CA—liver cancer	1.84e-06	1.12e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CB—liver cancer	1.82e-06	1.11e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CA—liver cancer	1.74e-06	1.06e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—liver cancer	1.6e-06	9.75e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—liver cancer	1.51e-06	9.18e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—liver cancer	1.51e-06	9.16e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CA—liver cancer	1.43e-06	8.67e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—liver cancer	1.42e-06	8.65e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CA—liver cancer	1.3e-06	7.9e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—liver cancer	1.16e-06	7.08e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CA—liver cancer	1.11e-06	6.75e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—liver cancer	1.06e-06	6.45e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—liver cancer	9.08e-07	5.52e-06	CbGpPWpGaD
